Leonetti G, Pasotti C, Ferrari G P, Zanchetti A
Acta Med Scand Suppl. 1984;681:137-41. doi: 10.1111/j.0954-6820.1984.tb08688.x.
Verapamil, a calcium antagonist, was compared with propranolol, a widely used beta-adrenoreceptor blocker, in hypertensive patients with respect to its antihypertensive efficacy and incidence and severity of adverse effects. Both drugs caused similar blood pressure reductions without interfering with pulse pressure. The hypotensive effect of verapamil was not accompanied by any effect on heart rate, while after propranolol there was a significant bradycardia. ST-segment and T wave abnormalities at rest and after exercise were partially or completely reverted by both drugs. The incidence and severity of adverse effects was very low and no patient was withdrawn from the study because of complaints due to the active drugs. Verapamil can be compared as antihypertensive drug to the beta-blocker propranolol and this may justify, together with the absence of negative effects on lipids, blood sugar, serum electrolytes and renal function, its use as an antihypertensive drug of first choice.
将钙拮抗剂维拉帕米与广泛使用的β-肾上腺素能受体阻滞剂普萘洛尔在高血压患者中就其降压疗效以及不良反应的发生率和严重程度进行了比较。两种药物引起的血压降低相似,且不影响脉压。维拉帕米的降压作用未伴随对心率的任何影响,而普萘洛尔用药后出现显著心动过缓。静息及运动后的ST段和T波异常在两种药物治疗后均部分或完全恢复。不良反应的发生率和严重程度非常低,没有患者因活性药物引起的不适而退出研究。维拉帕米作为一种降压药物可与β受体阻滞剂普萘洛尔相媲美,这一点连同其对血脂、血糖、血清电解质和肾功能无负面影响,可能证明其作为一线降压药物使用是合理的。